Treatment of relapsing polychondritis in the era of biological agents.

Hdl Handle:
http://hdl.handle.net/10147/207782
Title:
Treatment of relapsing polychondritis in the era of biological agents.
Authors:
McCarthy, Eoghan M; Cunnane, Gaye
Affiliation:
Department of Rheumatology, St James' Hospital, Dublin 8, Ireland.
Citation:
Rheumatol Int. 2010 Apr;30(6):827-8. Epub 2009 Dec 18.
Journal:
Rheumatology international
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207782
DOI:
10.1007/s00296-009-1308-6
PubMed ID:
20020132
Abstract:
Relapsing polychondritis (RP) is a rare disorder, often requiring high doses of immunosuppressive therapy to control its potentially life-threatening consequences. The advent of biological agents has added to the armamentarium available to treat RP, but the lack of controlled trials, along with the small numbers of patients and disease heterogeneity means that new therapies are prescribed without the benefits of rigorous clinical research. Thus, information on individual cases is of value in expanding our knowledge of the use of biologic agents in rare conditions. We report on the use of rituximab in a patient who subsequently developed catastrophic aortic incompetence, and we review the literature in relation to the use of this drug in RP.
Language:
eng
MeSH:
Antibodies, Monoclonal/*therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents/therapeutic use; Aortic Valve/drug effects/pathology/surgery; Aortic Valve Insufficiency/*drug therapy/*immunology/surgery; Azathioprine/therapeutic use; C-Reactive Protein/metabolism; Cardiac Surgical Procedures; Collagen/immunology; Hearing Loss, Sensorineural/etiology/surgery; Humans; Immunity, Cellular/drug effects/immunology; Immunosuppressive Agents/*therapeutic use; Lymphocyte Activation/drug effects/immunology; Male; Middle Aged; Polychondritis, Relapsing/*complications/*drug therapy/physiopathology; Treatment Outcome
ISSN:
1437-160X (Electronic); 0172-8172 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMcCarthy, Eoghan Men_GB
dc.contributor.authorCunnane, Gayeen_GB
dc.date.accessioned2012-02-01T10:44:33Z-
dc.date.available2012-02-01T10:44:33Z-
dc.date.issued2012-02-01T10:44:33Z-
dc.identifier.citationRheumatol Int. 2010 Apr;30(6):827-8. Epub 2009 Dec 18.en_GB
dc.identifier.issn1437-160X (Electronic)en_GB
dc.identifier.issn0172-8172 (Linking)en_GB
dc.identifier.pmid20020132en_GB
dc.identifier.doi10.1007/s00296-009-1308-6en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207782-
dc.description.abstractRelapsing polychondritis (RP) is a rare disorder, often requiring high doses of immunosuppressive therapy to control its potentially life-threatening consequences. The advent of biological agents has added to the armamentarium available to treat RP, but the lack of controlled trials, along with the small numbers of patients and disease heterogeneity means that new therapies are prescribed without the benefits of rigorous clinical research. Thus, information on individual cases is of value in expanding our knowledge of the use of biologic agents in rare conditions. We report on the use of rituximab in a patient who subsequently developed catastrophic aortic incompetence, and we review the literature in relation to the use of this drug in RP.en_GB
dc.language.isoengen_GB
dc.subject.meshAntibodies, Monoclonal/*therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Murine-Deriveden_GB
dc.subject.meshAntirheumatic Agents/therapeutic useen_GB
dc.subject.meshAortic Valve/drug effects/pathology/surgeryen_GB
dc.subject.meshAortic Valve Insufficiency/*drug therapy/*immunology/surgeryen_GB
dc.subject.meshAzathioprine/therapeutic useen_GB
dc.subject.meshC-Reactive Protein/metabolismen_GB
dc.subject.meshCardiac Surgical Proceduresen_GB
dc.subject.meshCollagen/immunologyen_GB
dc.subject.meshHearing Loss, Sensorineural/etiology/surgeryen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunity, Cellular/drug effects/immunologyen_GB
dc.subject.meshImmunosuppressive Agents/*therapeutic useen_GB
dc.subject.meshLymphocyte Activation/drug effects/immunologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPolychondritis, Relapsing/*complications/*drug therapy/physiopathologyen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleTreatment of relapsing polychondritis in the era of biological agents.en_GB
dc.contributor.departmentDepartment of Rheumatology, St James' Hospital, Dublin 8, Ireland.en_GB
dc.identifier.journalRheumatology internationalen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.